Comparison of ceftriaxone with cefotaxime in serious chest infections - PubMed

Abstract

Ceftriaxone is a new, third-generation cephalosporin that, because of its long half-life, offers potential advantages of cost and convenience over similar agents such as cefotaxime. We compared the two drugs in a prospective, randomized study of the treatment of chest infections in seriously ill patients. Fifty-one patients (90 percent of whom were mechanically ventilated) received either ceftriaxone, 2g IV once daily, or cefotaxime, 2 g IV thrice daily, for five days. The two groups of patients appeared demographically comparable. Ceftriaxone in a single daily dose of 2 g once daily may not be satisfactory for the treatment of serious chest infections.

Similar articles

• Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections.

  Simmons BP, Gelfand MS, Grogan J, Craft B. Simmons BP, et al. Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):155-7. doi: 10.1016/0732-8893(95)00080-t. Diagn Microbiol Infect Dis. 1995. PMID: 7587031 Clinical Trial.

• Ceftriaxone compared with cefotaxime for serious bacterial infections.

  Smith CR, Petty BG, Hendrix CW, Kernan WN, Garver PL, Fox K, Beamer A, Carbone K, Threlkeld M, Lietman PS. Smith CR, et al. J Infect Dis. 1989 Sep;160(3):442-7. doi: 10.1093/infdis/160.3.442. J Infect Dis. 1989. PMID: 2668428 Clinical Trial.

• Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study.

  Mandell LA, Bergeron MG, Ronald AR, Vega C, Harding G, Saginur R, Feld R, Duperval R, Landis SJ, Miedzinski LJ, et al. Mandell LA, et al. J Infect Dis. 1989 Sep;160(3):433-41. doi: 10.1093/infdis/160.3.433. J Infect Dis. 1989. PMID: 2668427 Clinical Trial.

• Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.

  Plosker GL, Foster RH, Benfield P. Plosker GL, et al. Pharmacoeconomics. 1998 Jan;13(1 Pt 1):91-106. doi: 10.2165/00019053-199813010-00009. Pharmacoeconomics. 1998. PMID: 10175990 Review.

• Ceftriaxone: a third-generation cephalosporin.

  Nahata MC, Barson WJ. Nahata MC, et al. Drug Intell Clin Pharm. 1985 Dec;19(12):900-6. doi: 10.1177/106002808501901203. Drug Intell Clin Pharm. 1985. PMID: 3910386 Review.

Cited by

• Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

  Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Kalil AC, et al. Clin Infect Dis. 2016 Sep 1;63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14. Clin Infect Dis. 2016. PMID: 27418577 Free PMC article.

• Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

  Nath SK, Foster GA, Mandell LA, Rotstein C. Nath SK, et al. Can J Infect Dis. 1995 Jan;6(1):21-7. doi: 10.1155/1995/617610. Can J Infect Dis. 1995. PMID: 22514377 Free PMC article.

• Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

  Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, McTaggart B, Weiss K, Zhanel GG. Rotstein C, et al. Can J Infect Dis Med Microbiol. 2008 Jan;19(1):19-53. doi: 10.1155/2008/593289. Can J Infect Dis Med Microbiol. 2008. PMID: 19145262 Free PMC article.

• [Parenteral cephalosporins for the treatment of lower respiratory tract infections].

  Vogel F. Vogel F. Infection. 1993;21 Suppl 1:S28-34. doi: 10.1007/BF01710341. Infection. 1993. PMID: 8314290 Review. German.

• The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.

  Jones RN. Jones RN. Infection. 1994;22 Suppl 3:S152-60. doi: 10.1007/BF01782700. Infection. 1994. PMID: 7843824 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information